Edwards Lifesciences Corp (EW)vsStandard Biotools Inc (LAB)
EW
Edwards Lifesciences Corp
$105.80
-0.01%
HEALTHCARE · Cap: $59.81B
LAB
Standard Biotools Inc
$0.65
+1.31%
HEALTHCARE · Cap: $243.19M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 7806% more annual revenue ($6.67B vs $84.43M). LAB leads profitability with a 157.6% profit margin vs 15.3%. EW earns a higher WallStSmart Score of 54/100 (C-).
EW
Buy54
out of 100
Grade: C-
LAB
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.2%
Fair Value
$257.48
Current Price
$105.80
$151.68 discount
Margin of Safety
+89.2%
Fair Value
$11.06
Current Price
$0.65
$10.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 30.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Reasonable price relative to book value
Keeps 158 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -16.8% — below average capital efficiency
Revenue declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 30.1%. Revenue growth of 10.5% demonstrates continued momentum.
Bull Case : LAB
The strongest argument for LAB centers on Price/Book, Profit Margin, Debt/Equity. Profitability is solid with margins at 157.6% and operating margin at -41.7%.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 60.5x leaves little room for execution misses.
Bear Case : LAB
The primary concerns for LAB are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
EW profiles as a mature stock while LAB is a declining play — different risk/reward profiles.
LAB carries more volatility with a beta of 1.51 — expect wider price swings.
EW is growing revenue faster at 10.5% — sustainability is the question.
EW generates stronger free cash flow (507M), providing more financial flexibility.
Bottom Line
EW scores higher overall (54/100 vs 42/100), backed by strong 15.3% margins and 10.5% revenue growth. LAB offers better value entry with a 89.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Standard Biotools Inc
HEALTHCARE · MEDICAL DEVICES · USA
Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm's focus on developing high-performance products for laboratories in genomics and proteomics is aimed at improving research precision and operational efficiency. Utilizing proprietary platforms, Standard Biotools accelerates scientific discoveries, reinforcing its position as a leader in the dynamic biotechnology landscape. With a commitment to meeting the growing demand for innovative analytical solutions, LAB is strategically positioned to facilitate significant advancements within the life sciences sector.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?